Blood transfusion profile of Beta-Thalassemia Major patients attending a tertiary care hospital

  • Mallikarjun Adiveppa Pattanashetti Assistant Professor, Department of Pathology, S.Nijalingappa Medical College and HSK Hospital and Medical Research Centre, Bagalkot, Karnataka
  • Ganga S Pilli Professor, Department of Pathology, J N Medical College ,Belagavi , Karnataka
  • Laxmi Pattanashetti Assistant Professor, Department of Pharmacology , KLE College of Pharmacy, Belagavi, Karnataka
Keywords: β thalassemia, transfusion, chelation.

Abstract

Background: Beta (β) thalassemia major is most common monogenic disorder in the world. Around 1,00,000 children are born each year with the severe homozygous state of the disease in India. The objectives of this study was to assess clinical data and the blood transfusion profile of Beta thalassemia major patients attending tertiary care hospital. This was undertaken as very few studies have been done in this region of the vast country.Methods: The study was done at a tertiary care teaching hospital from January 2014 to December 2014. Universal sampling method was used and 35 β thalassemia major patients who received  blood transfusions at 2 to 4 weeks interval in the hospital were included in this study. Clinical details and blood transfusion record was collected on proforma for all patients and data interpreted.Result: Males (80%) outnumbered females (20%) with male to female ratio of 4:1. Nearly half of the study population was aged between 10 to 12 years (51.43). Majority of the patients had one blood transfusion per month (91.43%) and were on chelation therapy (71.43%). Majority of the patients received 100 to 125 blood transfusions during their lifetime        (28.57 %). Least number of blood transfusions of more than 250 transfusions was taken by one patient (2.86 %).Conclusion: The present study describes the transfusion profile of β thalassemia major patients attending the tertiary care hospital and emphasizes on  maintenance of transfusion record of b thalassemia major patients for better management of these patients. DOI: 10.21276/APALM.1269

References

1. Cao A, Galanello R. Beta thalassemia. Genet Med 2010;12:61-76.
2. Management of birth defects and haemoglobin disorders: Report of a Joint WHO-March of Dimes Meeting. Geneva: World Health Organization; 2006.
3. Sarnaik, AS. Thalassemia and Related Hemoglobinopathies. Indian J Pediatr 2005;72(4):319-24.
4. Chern JP, Su S, Lin KH, Chang SH, Lu MY, Jou ST, et al. Survival, mortality and complications in patients with beta thalassaemia major in northern Taiwan. Pediatr Blood Cancer 2006;47:432-7.
5. Khalifa AS, Salem M, Mounir E, El-Tawil MM, El-Sawy M, Abd Al-Aziz MM. Abnormal glucose tolerance in Egyptian beta-thalassemic patients: possible association with genotyping. Pediatr Diabetes 2004;5:126-32.
6. Najafipour F, Sorkhabi RS, Aghai NH, Zareizadeh M, Bahrami A. Importance of OGTT for diagnosis of Diabetes in thalassemia major patients J Gorgan Uni Med Sci 2008;10(3):71-6.
7. Mallik S, Chatterjee C, Mandal PK, Sardar JC, Ghosh P, Manna N. Expenditure to Treat Thalassaemia: An Experience at a Tertiary Care Hospital in India. Iranian J Publ Health 2010;39(1):78-84.
8. Rai ME, Tanoli ZM, Gandapur ASK. Clinical spectrum of patients of beta thalassemia: a review of fifty four patients. Glomal J Medical sciences 2005;3(2):55-60.
9. Guidelines for the Clinical Management of Thalassaemia. 2nd Revised ed., No. 9, Nicosia (CY): Thalassaemia International Federation; 2008.
Published
2017-04-19
Section
Original Article